

# MarÃ- a Jara-Acevedo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1420701/publications.pdf>

Version: 2024-02-01

42  
papers

2,546  
citations

279798

23  
h-index

265206

42  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2117  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. <i>Blood</i> , 2022, 139, 572-583.	1.4	8
2	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	4.6	39
3	Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas. <i>Frontiers in Oncology</i> , 2021, 11, 740782.	2.8	5
4	STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. <i>Cancers</i> , 2020, 12, 3508.	3.7	34
5	Analysis of gene variants in the GASH/Sal model of epilepsy. <i>PLoS ONE</i> , 2020, 15, e0229953.	2.5	16
6	Complete Multilineage CD4 Expression Defect Associated With Warts Due to an Inherited Homozygous CD4 Gene Mutation. <i>Frontiers in Immunology</i> , 2019, 10, 2502.	4.8	15
7	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 552.	4.1	9
8	Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. <i>Blood</i> , 2019, 134, 456-468.	1.4	44
9	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	5.2	42
10	<i>KIT</i> D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-16.	0.4	2
11	Systemic mastocytosis with <i>KIT</i> V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 21.	2.0	5
12	A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 99-106.	2.8	22
13	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature. <i>Oncotarget</i> , 2017, 8, 68950-68963.	1.8	83
14	<i>KIT</i> D816V mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. <i>Blood</i> , 2016, 127, 761-768.	1.4	33
15	Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. <i>British Journal of Haematology</i> , 2016, 172, 56-63.	2.5	15
16	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 168-178.e1.	2.9	72
17	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 49-59.	3.3	47
18	Detection of the <i>KIT</i> D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Modern Pathology</i> , 2015, 28, 1138-1149.	5.5	88

#	ARTICLE	IF	CITATIONS
19	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. <i>Oncotarget</i> , 2015, 6, 42938-42951.	1.8	23
20	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 155-162.	3.5	23
21	Flow Cytometry in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 297-313.	1.9	14
22	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	2.9	118
23	<scp>CD</scp>30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	2.9	77
24	Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas. <i>BMC Medical Genetics</i> , 2013, 14, 114.	2.1	16
25	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1213-1224.e4.	2.9	30
26	Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 605-607.	2.9	27
27	Flow Cytometry Criteria for Systemic Mastocytosis: Bone Marrow Mast Cell Counts Do Not Always Count. <i>American Journal of Clinical Pathology</i> , 2013, 139, 404-406.	0.7	6
28	Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e76116.	2.5	29
29	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e126-e129.	1.6	59
30	Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. <i>Modern Pathology</i> , 2012, 25, 516-521.	5.5	55
31	Evaluation of chemically modified carrier proteins for developing monoclonal antibodies against a clinically relevant mutation of cKIT. <i>Journal of Immunological Methods</i> , 2012, 384, 171-176.	1.4	5
32	Diagnosis of Adult Mastocytosis: Role for Bone Marrow Analysis. , 2012, , 388-398.		6
33	Nanotechniques in proteomics: Protein microarrays and novel detection platforms. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 499-506.	4.0	75
34	The Proliferation Index of Specific Bone Marrow Cell Compartments from Myelodysplastic Syndromes Is Associated with the Diagnostic and Patient Outcome. <i>PLoS ONE</i> , 2012, 7, e44321.	2.5	16
35	Evaluation of the WHO criteria for the classification of patients with mastocytosis. <i>Modern Pathology</i> , 2011, 24, 1157-1168.	5.5	89
36	Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. <i>Haematologica</i> , 2011, 96, e26-e26.	3.5	4

#	ARTICLE	IF	CITATIONS
37	Cell cycle distribution of different cell compartments in normal versus reactive bone marrow: A frame of reference for the study of dysplastic hematopoiesis. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 354-361.	1.5	18
38	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 719-726.e4.	2.9	128
39	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1269-1278.e2.	2.9	263
40	Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 514-521.	2.9	252
41	Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. <i>Blood</i> , 2009, 114, 33-37.	1.4	183
42	KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. <i>Blood</i> , 2006, 108, 2366-2372.	1.4	447